Baker Bros. Advisors’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Baker Bros. Advisors’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,035,786	Closed	-$48.1M	–	115
2023 Q2	$48.1M	Hold	1,035,786	–	–	0.28%	24
2023 Q1	$29.7M	Buy	1,035,786 +173,579	+20%	+$5.14M	0.16%	31
2022 Q4	$26.9M	Buy	862,207 +273,972	+47%	+$8.93M	0.16%	33
2022 Q3	$11.9M	Hold	588,235	–	–	0.08%	59
2022 Q2	$9.13M	Hold	588,235	–	–	0.05%	62
2022 Q1	$11.3M	Hold	588,235	–	–	0.06%	61
2021 Q4	$14.9M	Hold	588,235	–	–	0.07%	66
2021 Q3	$19.3M	Buy	+588,235	New	+$20M	0.08%	64

Baker Bros. Advisors's DICE Position: Q3 2023 in Review

Baker Bros. Advisors sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 1,035,786 shares — an estimated $48.1M sold.

Baker Bros. Advisors first reported a position in DICE in Q3 2021 and held it in 8 quarters. The position peaked at $48.1M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

Baker Bros. Advisors reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Baker Bros. Advisors sold 1,035,786 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $48.1M.
Baker Bros. Advisors first reported a position in DICE Therapeutics, Inc. Common Stock in Q3 2021 and held it in 8 quarters.
Baker Bros. Advisors's DICE Therapeutics, Inc. Common Stock position peaked at $48.1M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.